Bulletin
Investor Alert

Market Pulse Archives

May 29, 2020, 5:16 p.m. EDT

Moderna begins new COVID-19 vaccine study

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)

or Cancel Already have a watchlist? Log In

By Jeremy C. Owens

MRNA

Moderna Inc. /zigman2/quotes/205619834/composite MRNA -3.63% announced Friday afternoon that the latest study of its potential COVID-19 vaccine has begun. The first participants in each age range have been dosed with its vaccine candidate, known as mRNA-1273, and will receive another dose 28 days later before being followed for 12 months to determine efficacy. The company intends to enroll 600 patients in the study across two age groups, 18 to 55 and older than 55. Moderna previously released limited details about its phase 1 trial of the vaccine, saying that it produced necessary antibodies in some subjects but neglecting to provide full datasets. Moderna stock shot more than 10% higher Friday, with most of those gains coming in the last hour of the session. Shares were largely quiet in after-hours trading, when the announcement was made.

/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 62.61
-2.36 -3.63%
Volume: 7.41M
July 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$25.26 billion
Rev. per Employee
$177,721
loading...

Get news alerts on Moderna Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.